Structured, descriptive approaches are utilized by drug regulatory agencies to support and communicate approval decisions about human drugs and biologics. The US Food and Drug Administration (FDA) uses the Benefit–Risk Framework (BRF), which has been integrated into its drug review process. This paper reviews how FDA review teams have used the BRF to communicate approval decisions.
This paper (1) uses content analysis to systematically review the decision factors communicated by FDA review teams in all BRFs associated with novel drugs approved by FDA in 2017–2018 and (2) presents a case study about how the BRF was used for three drugs approved for HIV-1 in 2018–2019.
The content analysis found most BRFs for novel drug approvals communicate what we call an “urgent” context and complicating decision factors around benefit and/or risk; the HIV-1 case study highlights the flexibility of the structured BRF tool.
FDA’s BRF provides a flexible mechanism for communicating important decision factors, allowing it to support the diversity of drug approval decisions made by FDA.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
US Department of Health and Human Services. Adequate and well-controlled studies. 21 CFR §314.126 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.126.
Gassman AL, Nguyen CP, Joffe HV. FDA regulation of prescription drugs. N Engl J Med. 2017;376(7):674–82.
Smith MY, Benattia I, Strauss C, Bloss L, Jiang Q. Structured benefit-risk assessment across the product lifecycle: practical considerations. Ther Innov Regul Sci. 2017;51(4):501–8.
Wang J, Wolka A, Bullok K, Anglin G, Radawski C, Noel R. Implementation of structured benefit–risk assessments in marketing authorization applications: lessons learned. Ther Innov Regul Sci. 2016;50(6):718–23.
Juhaeri J. Benefit-risk evaluation: the past, present and future. Ther Adv Drug Saf. 2019;10:2042098619871180.
Pharmaceuticals & Medical Devices Agency. Points to Be Considered by the Review Staff Involved in the Evaluation Process of a New Drug April 17, 2008. https://www.pmda.go.jp/files/000153830.pdf#page=1.
International Converence on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Revision of M4E Guideline on Enhancing the Format and Structure of Benefit-Risk Information in ICH: Efficacy M4E(R2). June 15, 2016. https://database.ich.org/sites/default/files/M4E_R2__Guideline.pdf.
Centre for Innovation in Regulatory Science. The CIRS-BRAT Framework 2014. https://www.cirs-brat.org/.
Levitan B, Phillips LD, Walker S. Structured approaches to benefit-risk assessment: A case study and the patient perspective. Ther Innov Regul Sci. 2014;48(5):564–73.
Nixon R, Dierig C, Mt-Isa S, Stockert I, Tong T, Kuhls S, et al. A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment. Biom J. 2016;58(1):8–27.
Mt-Isa S, Hallgreen CE, Wang N, Callreus T, Genov G, Hirsch I, et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf. 2014;23(7):667–78.
Miller KL, Woodcock J. Value assessment in the regulatory context. Value Health. 2017;20(2):296–8.
Food and Drug Administration. Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making: Draft PDUFA V Implementation Plan Fiscal Years 2013–2017. February 2013. https://www.fda.gov/media/84831/download.
Food and Drug Administration. Benefit-Risk Assessment in Drug Regulatory Decision-Making: Draft PDUFA VI Implementation Plan (FY 2018–2022). March 30, 2018. https://www.fda.gov/media/112570/download.
Food and Drug Administration. Benefit-Risk Assessment Throughout the Drug Lifecycle: FDA Discussion Document. May 3, 2019. https://healthpolicy.duke.edu/sites/default/files/2020-07/discussion_guide_b-r_assessment_may16_0.pdf.
Lee Abbott M, McKinney J. Understanding and Applying Research Design. Hoboken: Wiley; 2013.
Rosenthal R, Rosnow RL. Essentials of Behavioral Research: Methods and Data Analysis. 2nd ed. New York: McGraw Hill; 1984.
Food and Drug Administration. Advancing Health Through Innovation: 2017 New Drug Therapy Approvals. January 2018. https://www.fda.gov/media/110526/download.
Food and Drug Administration. Advancing Health Through Innovation: 2018 New Drug Therapy Approvals. January 2019. https://www.fda.gov/media/120357/download.
Hughes D, Waddingham E, Mt-Isa S, Goginsky A, Chan E, Downey GF, et al. Recommendations for benefit-risk assessment methodologies and visual representations. Pharmacoepidemiol Drug Saf. 2016;25(3):251–62.
Raju GK, Gurumurthi K, Domike R, Weinstock C, Singh H, Kluetz P, et al. Using a benefit risk analysis approach to capture regulatory decision-making: renal cell carcinoma. Clin Pharmacol Ther. 2019;107:495–506.
European Medicines Agency. <Co>Rapporteur day <60*><80> critical assessment report: Overview and list of questions. 2019. https://www.ema.europa.eu/documents/template-form/day-80-assessment-report-overview-d120-loq-template-guidance-rev-1019_en.doc.
Walker S, McAuslane N, Liberti L, Leong J, Salek S. A universal framework for the benefit-risk assessment of medicines: is this the way forward? Ther Innov Regul Sci. 2015;49(1):17–25.
We thank the Division of Antiviral Products (Office of New Drugs, CDER, FDA) for helpful discussion to inform the case study. We also thank staff and leadership in the Office of New Drugs (CDER, FDA) for helpful feedback.
No funding was obtained for this research.
Conflict of interest
The authors are employed by the Center for Drug Evaluation and Research at the FDA. They have no other conflicts to disclose. This publication reflects the views of the authors and should not be construed to represent FDA’s views or policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lackey, L., Thompson, G. & Eggers, S. FDA’s Benefit–Risk Framework for Human Drugs and Biologics: Role in Benefit–Risk Assessment and Analysis of Use for Drug Approvals. Ther Innov Regul Sci 55, 170–179 (2021). https://doi.org/10.1007/s43441-020-00203-6
- Benefit–risk assessment
- Content analysis